Literature DB >> 352466

Prostacyclin (PGI2) inhibits the formation of platelet thrombi in arterioles and venules of the hamster cheek pouch.

E A Higgs, G A Higgs, S Moncada, J R Vane.   

Abstract

1 Isolated rings of hamster aorta produced an unstable substance which inhibited platelet aggregation in vitro and had the same characteristics as prostacyclin. 2 Prostacyclin inhibited adenosine diphosphate (ADP)-induced aggregation of hamster platelets in vitro. 3 The effects of prostacyclin on ADP-induced platelet thrombi in the microcirculation of the hamster cheek pouch were studied with a television microscope. 4 Prostacyclin caused a dose-dependent increase in the time of iontophoretic application of ADP which was required to induce platelet thrombi formation and embolization in venules (30 to 40 micron diameter). 5 Prostacyclin caused a dose-dependent reduction in the total time during which ADP-induced thrombi were observed following local electrical damage to arterioles (40 to 80 micron diameter). 6 Thrombus formation in venules and arterioles was abolished by 500 ng/ml prostacyclin in the Krebs solution superfusing the hamster cheek pouch. 7 Prostacyclin was approximately twenty times more potent than prostaglandin E1 in preventing thrombus formation in the microcirculation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 352466      PMCID: PMC1668093          DOI: 10.1111/j.1476-5381.1978.tb07809.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Aggregation of blood platelets by adenosine diphosphate and its reversal.

Authors:  G V BORN
Journal:  Nature       Date:  1962-06-09       Impact factor: 49.962

2.  Modulation of thrombus formation in vivo by prostaglandins [proceedings].

Authors:  J Westwick
Journal:  Br J Pharmacol       Date:  1977-09       Impact factor: 8.739

3.  Synthesis and sterochemistry of prostacyclin and synthesis of 6-ketoprostagliandin F1alpha.

Authors:  R A Johnson; F H Lincoln; J L Thompson; E G Nidy; S A Mizak; U Axen
Journal:  J Am Chem Soc       Date:  1977-06-08       Impact factor: 15.419

4.  Prostacyclin as a potent dilator of arterioles in the hamster cheek pouch [proceedings].

Authors:  G A Higgs; S Moncada; J R Vane
Journal:  J Physiol       Date:  1978-02       Impact factor: 5.182

5.  Growth rate in vivo of platelet thrombi, produced by iontophoresis of ADP, as a function of mean blood flow velocity.

Authors:  N Begent; G V Born
Journal:  Nature       Date:  1970-08-29       Impact factor: 49.962

6.  The chemical structure of prostaglandin X (prostacyclin).

Authors:  N Whittaker; S Bunting; J Salmon; S Moncada; J R Vane; R A Johnson; D R Morton; J H Kinner; R R Gorman; J C McGuire; F F Sun
Journal:  Prostaglandins       Date:  1976-12

7.  A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation.

Authors:  S Moncada; R J Gryglewski; S Bunting; J R Vane
Journal:  Prostaglandins       Date:  1976-11

8.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.

Authors:  S Moncada; R Gryglewski; S Bunting; J R Vane
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

9.  Prostacyclin (PGI2) inhibits the formation of platelet thrombi induced by adenosine diphosphate (ADP) in vivo [proceedings].

Authors:  G A Higgs; S Moncada; J R Vane
Journal:  Br J Pharmacol       Date:  1977-09       Impact factor: 8.739

10.  Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.

Authors:  S Moncada; E A Higgs; J R Vane
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

View more
  7 in total

Review 1.  Physiology and pharmacology of prostaglandins.

Authors:  S J Konturek; W Pawlik
Journal:  Dig Dis Sci       Date:  1986-02       Impact factor: 3.199

Review 2.  Prostaglandin I2 (prostacyclin).

Authors:  J G Kelton; M A Blajchman
Journal:  Can Med Assoc J       Date:  1980-01-26       Impact factor: 8.262

3.  The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.

Authors:  Subhashini Srinivasan; Fozia Mir; Jin-Sheng Huang; Fadi T Khasawneh; Stephen C-T Lam; Guy C Le Breton
Journal:  J Biol Chem       Date:  2009-04-03       Impact factor: 5.157

4.  Prostacyclin reverses platelet stress fibre formation causing platelet aggregate instability.

Authors:  M Z Yusuf; Z Raslan; L Atkinson; A Aburima; S G Thomas; K M Naseem; S D J Calaminus
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

5.  Compassionate use of Pulmonary Vasodilators in Acute Severe Hypoxic Respiratory Failure due to COVID-19.

Authors:  Lewis Matthews; Laurence Baker; Matteo Ferrari; Weronika Sanchez; John Pappachan; Mike Pw Grocott; Ahilanandan Dushianthan
Journal:  J Intensive Care Med       Date:  2022-04-04       Impact factor: 2.889

6.  Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation.

Authors:  Fabián Santana-Romo; Carlos F Lagos; Yorley Duarte; Francisco Castillo; Yanina Moglie; Miguel A Maestro; Nitin Charbe; Flavia C Zacconi
Journal:  Molecules       Date:  2020-01-23       Impact factor: 4.411

7.  Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension.

Authors:  Aleksandra Gąsecka; Marta Banaszkiewicz; Rienk Nieuwland; Edwin van der Pol; Najat Hajji; Hubert Mutwil; Sylwester Rogula; Wiktoria Rutkowska; Kinga Pluta; Ceren Eyileten; Marek Postuła; Szymon Darocha; Zenon Huczek; Grzegorz Opolski; Krzysztof J Filipiak; Adam Torbicki; Marcin Kurzyna
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.